May 24, 2016 / 11:32 AM / a year ago

BRIEF-Theratechnologies says 82.5 pct of patients achieved the primary endpoint in late-stage trial of HIV drug

1 Min Read

May 24 (Reuters) - Theratechnologies

* Notified by partner of results for primary end point of phase iii trial with ibalizumab in patients with multi-drug resistant hiv-1

* Theratechnologies announces that 82.5% of patients achieved the primary endpoint in the phase iii ibalizumab trial Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below